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n recent years, experience in microneurosurgical techniques, endovascular coiling, and extended resources in neurointensive care has enabled the treatment of patients with severe aneurysmal subarachnoid hemorrhage (SAH) (18, 24, 30, 37) . These patients, however, have a high incidence of specific complications, such as severe brain edema with elevations of intracranial pressure (ICP) and cerebral vasospasm (CVS) leading to secondary ischemic infarctions (10, 11, 14) .
Mild hypothermia, showing numerous neuroprotective effects, may serve as an effective treatment option if elevated ICP and/or symptomatic CVS are refractory to conventional treatment (5, 8, 12, 39, 44, 48, 53, 54) . Thus far, only a few clinical studies, based on small series of patients with SAH and hypothermia treatment as a result of intracranial hypertension or CVS, have been reported (19, 29, 31, 40, 41) .
The purpose of the present study was to evaluate the feasibility and safety of therapeutic hypothermia in patients with SAH and intracranial hypertension and/or CVS resistant to conventional treatment. The outcome of 100 consecutive patients was studied, focusing especially on possible side effects of the specific treatment.
PATIENTS AND METHODS
This study was approved as a part of Project E-015/99 by the Ethics Committee of the University of Zurich. Between January 1999 and February 2007, 441 patients with SAH were admitted to the Department of Neurosurgery, University Hospital Zurich, and underwent aneurysm clipping or coiling within 3 days.
Structured Treatment
All patients were managed according to a standardized treatment protocol for aneurysmal SAH and vasospasm (34) . Emergency treatment of elevated ICP consisted of sedation with intubation, osmotherapy (20% mannitol and hypertonic NaCl-hydroxyethyl-starch solution), and thiopental boluses in a dose of 5 to 10 mg/kg. Aneurysm clipping or coiling was performed within hours after emergency diagnostic evaluation with angiography or computed tomographic (CT) angiography. Patients with poor-grade SAH and severe brain edema remained sedated (fentanyl infusion [2-8 μg/kg/h] and midazolam [0.1-0.4 mg/kg/h]) after surgery. A ventricular catheter (Raumedic AG, Münchberg, Germany), an intraparenchymatous probe (Raumedic AG) or, in the early stage of this series, a subdural probe (NMT Neuroscience, Frankfurt, Germany) was inserted. In the absence of elevated ICP (Ͼ20 mm Hg) and signs of severe brain edema on a CT scan performed the first day after surgery, sedation was discon tinued to assess the patients' neurological status. All patients with SAH were treated with oral nimodipine. In cases of gastrointestinal reflux, nimodipine was administered intravenously. Dexamethasone (16 mg/d) was given for 2 days after hospital admission and then rapidly reduced by 4 mg every second day. Prophylactic antiepileptic treatment with phenytoine or valproate was initiated only in patients with elevated risk of seizures, patients presenting with World Federation of Neuro logical Societies Grade 3 or higher, patients with bleeding aneurysms in the middle cerebral artery territory, or patients with ischemic infarctions.
Treatment of Elevated ICP
If ICP was elevated (Ͼ20 mm Hg), treatment with intermittent cerebrospinal fluid drainage, osmotherapy, and mild hyperventilation was initiated. Patients with persistent ICP values greater than 20 mm Hg were eligible for treatment with barbiturate coma (adapted to a burst suppression pattern in continuous electroencephalographic monitoring). All patients under sedation because of intracranial hypertension were treated under extended monitoring of cerebral hemodynamics (monitoring of jugular bulb oxygen saturation, cerebral blood flow, and/or intraparenchymatous oxygen partial pressure) (15, 21, 35) . In patients showing signs of brain swelling during or immediately after craniotomy and aneurysm surgery (angry brain), the bone flap was not replaced and duraplasty was performed (primary decompressive craniectomy). The average diameter of craniectomy was 9 cm because of enlarged skin and bone opening in high-grade SAH patients with suspected brain edema. If elevated ICP values (Ͼ20 mm Hg) after surgery were resistant to conventional treatment and hypothermia, a secondary decompressive craniectomy with removal of frontal, temporal, and parietal bones (average diameter, 14-15 cm) and duraplasty was performed. 
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Treatment of CVS
Transcranial Doppler blood flow measurements were performed daily. A modified triple-H therapy (hypertension with systolic blood pressure Ͼ 150 mm Hg, normovolemia to minor hypervolemia, target hematocrit of 30%) was monitored with a PiCCO System (Pulsion Medical Systems AG, Munich, Germany) and induced if signs of CVS were present; e.g., development of delayed ischemic neurological deficits (after exclusion of hydrocephalus, electrolyte disturbance, or infection) in combination with increased transcranial Doppler blood flow velocities (mean middle cerebral artery blood flow velocities Ͼ 140 cm/s or increase Ͼ 50 cm/s within 24 hours) and/or perfusion deficits in perfusion CT scans. In comatose patients, intraparenchymatous oxygen partial pressure values less than 15 mm Hg or arteriojugular lactate differences greater than -0.2 mmol/L were regarded as highly suspicious for symptomatic CVS. To confirm and exclude CVS in comatose patients, angiography was performed regularly. If patients with delayed ischemic neurological deficits did not improve or worsened, angiography and treatment with percutaneous angioplasty and/or superselective papaverine infusion (total dose, 300 mg) into the vasospastic vessels were performed. In case of CVS recurrence, the papaverine infusion was repeated up to a total of 3 applications. Narrowing of the diameter of the vessel lumen greater than 30% was defined as angiographic evidence of CVS. Symptomatic CVS, resistant to or reoccurring after angioplasty and papaverine, was treated with barbiturate coma. New ischemic lesions that could not be attributed to other causes were considered to be CVS-induced infarctions.
Hypothermia Treatment
If ICP remained greater than 20 mm Hg and/or CVS was resistant to or recurring after the treatment mentioned above, hypothermia (target body core temperature, 33-34ЊC) under deep analgosedation was induced and maintained until ICP normalized and/or CVS resolved. Body core temperature was measured by a thermistor in the arterial line and, if tolerated, the rewarming rate was 1ЊC per day. Contraindications and criteria for early termination of hypothermia were severe pneumonia, signs of septic shock syndrome, coagulation disorder with manifest bleeding, and heart failure. From January 1999 until September 2000, hypothermia was induced and maintained in 10 patients using cooling blankets (Bair Hugger [Arizant Inc., Eden Prairie, MN] and Blanketrol [Cincinnati Sub-Zero, Cincinnati, OH]) and ice bags on the groin, axillae, and neck. Since October 2000 (90 patients), hypothermia was induced and maintained with an intravascular catheter-based heat exchange system (Alsius, Irvine, CA) (33) .
The following possible side effects of barbiturate coma and/or hypothermia were recorded: hypernatremia (Ͼ150 mmol/L), hyperkalemia (Ͼ5 mmol/L), and thrombocytopenia (Ͻ100,000/μL). Pneumonia was defined as new or progressive infiltrate in the chest x-ray, together with C-reactive protein values greater than 100 ng/L, a partial pressure of oxygen in arterial blood/fractional inspired oxygen index of less than 300 mm Hg, and positive microbiological cultures of tracheal aspirates. The acute respiratory distress syndrome was defined according to the American European Consensus Conference (partial pressure of oxygen in arterial blood/fractional inspired oxygen index Ͻ 300 mm Hg, bilateral infiltrates in chest x-ray, acute onset, pulmonary artery occlusion pressure Ͻ 18 mm Hg or no clinical suspicion of left atrial hypertension) (16) . Systemic inflammatory response with fever, hyperventilation, and tachycardia could not be deduced from classic symptoms in sedated and hypothermic patients. Therefore, the definition of septic shock syndrome was modified as volume-resistant shock (dosage of norepinephrine Ͼ 20 mcg/min or epinephrine Ͼ 1 mcg/min), minimum of 1 severe organ
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the presence of contraindications for barbiturate coma, and 87 patients were treated with hypothermia in combination with barbiturate coma. Severe SAH of Hunt and Hess Grades IV and V occurred in 66%, and Fisher Grades 3 and 4 in 92%, respectively. The mean duration of hypothermia treatment was 169 Ϯ 104 hours, with a maximum length of 16.4 days. Primary and/or secondary decompressive craniectomy because of persistent ICP greater than 20 mm Hg despite hypothermia treatment was performed in 52 patients (52%). External ventricular drains were inserted in 76 patients (76%). Thirty-two patients (32%) needed definitive ventriculoperitoneal or vetriculoatrial shunting during primary hospitalization.
Outcome
Overall outcome characteristics are summarized in Table 3 . The GOS score was evaluated 3 and 12 months after hospital discharge. In 10 patients, the 12-month evaluation has not been performed to date. Good functional outcome (GOS score, 4-5) was achieved in 30 patients (30.0%) after 3 months and in 32 
Outcome Measurements
Neurological outcome was assessed after 3 and 12 months by a neurologist in the outpatient clinic using the Glasgow Outcome Scale (GOS) score, with GOS 1 denominating death, GOS 2 vegetative state, GOS 3 severe disability, GOS 4 moderate disability, and GOS 5 mild or no disability (27) .
Statistical Analysis
Neurological outcome between the patient groups was compared by applying Fisher's exact test.
RESULTS
Patient and Treatment Characteristics
Between January 1999 and February 2007, a total of 441 patients with SAH were admitted and treated with early aneurysm clipping or coiling. Of these patients, 100 (23.1%) were treated with hypothermia because of intractable intracranial hypertension and/or refractory CVS, both occurring concurrently or subsequently during the course of the illness. Ninety-six patients were treated with clipping and 4 patients with coiling. Patient characteristics and the location of the aneurysms are given in Tables 1 and 2 . Thirteen percent of the patients were treated with hypothermia alone because of patients (35.6%) after 12 months. The number of patients surviving severely disabled (GOS score, 3) or in a vegetative state (GOS score, 2) decreased from 31.0% (n ϭ 31) to 16.7% (n ϭ 15) between the evaluation periods. The overall mortality rate after 12 months was 47.8%.
The 12-month outcome of patients divided into subgroups regarding age and indications for hypothermia treatment is displayed in Table 4 . Because of the high intergroup difference in sample size without significance, patients younger than 60 years tended to survive more often with good functional outcome, as compared with patients aged older than 60 years (39 versus 15.4%, not significant). The indications for hypothermia in all 100 patients were intractable intracranial hypertension alone (ICP group, 30%), resistant CVS alone (CVS group, 36%), and both (ICP/CVS group, 34%). GOS evaluation after 12 months in the ICP and combined ICP/CVS group was similar regarding good functional outcome (25.0 and 26.5%, not significant) and mortality (60.7 and 52.9%, not significant). In the CVS group, good functional outcome after 1 year was achieved significantly more often as compared with the ICP group (57.1 versus 25.0%, P ϭ 0.02) and the ICP/CVS group (57.1 versus 26.5%, P ϭ 0.025).
Side Effects
The rate of side effects occurring during hypothermia and until Day 7 after rewarming is listed in Table 5 . Of the 100 patients, 93 (93%) developed at least 1 side effect, possibly associated with hypothermia treatment. Hypernatremia and hyperkalemia occurred in 61 and 35 patients, limiting the duration of hypothermia and barbiturate coma in 31 and 28 cases, respectively. Among the 13 patients treated with hypothermia alone without barbiturate coma, hypernatremia occurred in 8 and hyperkalemia in 3 patients. One patient had to be treated with hemodiafiltration because of hyperkalemia. None of the patients died as a result of electrolyte disorders. Apart from atrial fibrillation, which could be kept under control with amiodarone, no hemodynamic relevant cardiac arrhythmias occurred. A thrombocyte count of less than 100/μL blood was observed in 47 patients and in 9 patients (69%) treated with hypothermia alone. One severe bleeding complication from a catheter insertion site with femoral hematoma and need for surgery occurred. Eighty-three patients suffered from severe infections, more than 50% of them in terms of ventilatorassociated pneumonia. Of the 13 patients treated with hypothermia alone, 10 (77%) developed severe infections. Clinically manifested venous thrombosis was validated by ultrasonography in 8 patients. Six patients died of severe side effects (respiratory or multi-organ failure) known to be associated with barbiturate coma and hypothermia.
DISCUSSION
In patients with refractory intracranial hypertension, mortality and disability rates increase up to 95 and 100%, respectively (11, 22, 38) . Symptomatic CVS, if resistant to treatment, leads to a devastating outcome (13, 14, 30) . In our study population, after all, good functional outcome was achieved in more than one-third of all patients (GOS score of 4-5 in 35.6% of patients) experiencing resistant intracranial hypertension and/or CVS. During the past decades, promising studies on intraoperative hypothermia during aneurysm surgery as an attempt to reduce ischemic injury have been published (7, 23, 28, 42, 49, 50) . Todd et al. (56) , applying intraoperative hypothermia in a randomized study in 1001 patients with good-grade SAH, however, demonstrated no improvement in neurological outcome 3 months after aneurysm surgery. This suggests that only a carefully selected subgroup of patients, with specific complications induced by SAH, may benefit from hypothermia treatment at a particular time and for a certain duration.
In the present series, good functional outcome could be achieved in 39% of patients younger than 60 years and in 15.4% of those older than 60 years. A recent multivariate analysis of the 4 tirilazad trials demonstrated that increasing age is associated with unfavorable outcome (47) . In a recent analysis of 350 patients with SAH in 22 Italian neurosurgical centers, Citerio et al. (10) found, on the basis of a logistic regression model, that age older than 60 years was an independent predictor of unfavorable outcome (odds ratio, 3; 95% confidence interval, 1.7-5.3). This effect may be even more pronounced in a subgroup of patients with high severity grade, most severe illness course, and a treatment procedure associated with severe side effects.
The most encouraging results were achieved in patients with resistant CVS without intracranial hypertension (good functional outcome in 57.1%). Hypothermia was induced as early and fast as possible if symptoms of CVS, refractory to conventional treatment, occurred. Several models of ischemia demonstrated that hypothermia, induced during or early after ischemia, is effective in minimizing neuronal damage after SAH (20, 44, 54) . Piepgras et al. (44) investigated the mean apparent diffusion coefficient as a marker of ischemic damage after SAH with normothermia and hypothermia, induced up to 60 minutes after SAH in rats. They concluded that initiation and duration of the hypothermia period seems to be of importance. Thomé et al. (54, 55) demonstrated that pre-and postinsult hypothermia (32ЊC) reverses acute cerebral perfusion pressure-independent hypoperfusion after cisternal blood injection in rats. Kawamura et al. (32) demonstrated the neuroprotective effects of hypothermia via reduction of the stress response after experimental SAH. As intracranial hypertension is a late consequence of global cerebral edema after SAH, these animal studies encourage early induction of hypothermia in high-grade SAH; e.g., as soon as signs of brain swelling are visible in admission CT scans or intraoperatively.
To date, only a few clinical case reports or small series applying hypothermia to minimize damage after SAH have been published. Of a series of 12 patients with life-threatening refractory CVS treated with barbiturate coma, Kassell et al. (29) (41) performed hypothermia treatment (32-34ЊC) in 8 patients with severe CVS showing progressive ischemic neurological deficits that were refractory to conventional therapies, and in patients who underwent delayed aneurysm clipping with delayed neurological deficits. Good recovery after 5 to 10 days of hypothermia treatment could be achieved in 5 patients and moderate disability could be achieved in 2 patients.
Prolonged systemic hypothermia may be associated with severe side effects, thus possibly negating potential benefits (9, 19, 29, 44, 45) . The mean duration of hypothermia in our patients was 7 days (up to a maximum of 16 days) and was adjusted to the duration of ICP elevations and the persistence of CVS, matching the occurrence and severity of side effects. The incidence of side effects was high, compared with studies applying hypothermia treatment for 12 to 24 hours (4, 25) , suggesting that the longer patients are treated with hypothermia, the more often side effects might occur (4, 19, 25) . Nearly all of our patients showed side effects that are associated with and/or possibly induced by hypothermia treatment.
With 52, 40, and 16%, respectively, the incidence of ventilator-associated pneumonia, septic shock syndrome, and acute respiratory distress syndrome was high. Hypothermia and barbiturate coma suppress inflammatory reactions, inhibit neutrophil and macrophage function, and release proinflammatory cytokines (1, 6, 36, 52) . However, only 6 patients died from respiratory or multi-organ failure. In 1999, a strict protocol for treatment of elevated ICP and CVS, as well as prevention and treatment of side effects of systemic hypothermia and barbiturate coma, was introduced in our neurocritical care unit (34, 37) . Thrombocytopenia, occurring in nearly half of the patients, was counteracted vigorously by administration of platelets. Hemorrhagic diathesis, because of platelet dysfunction, and changed kinetic of clotting enzymes are known to be associated with long-term hypothermia treatment (2, 57) . Therefore, in our patients, we transfused platelets when they dropped below 100/μL. Furthermore, regarding hypothermia treatment, our protocol limits the use of other drugs and plasma substitutes hampering platelet aggregation, such as hydroxyethyl starch solution and valproate, while preferring fluid and volume substitution with cristalloids and fresh frozen plasma. With this regimen, only 1 patient experienced severe bleeding complications.
Several studies have reported electrolyte disorders induced by hypothermia and barbiturate treatment (1, 9, 46) . Although hypernatremia may be controlled with desmopressin and slow infusion of slightly hypo-osmotic cristalloids, one has to be especially alert to the occurrence of potentially dangerous hyperkalemia, which occurred in one-third of our patients. Although rebound hyperkalemia after severe hypokalemia refractory to potassium therapy is described to be associated with barbiturate coma, and most patients were treated with both hypothermia and barbiturates, it also occurred in 3 patients treated with hypothermia alone (9). Polderman et al. (46) found that hypothermia in trauma patients was commonly associated with hypokalemia, hypophosphatemia, and hypomagnesemia. Normo-and hypothermic patients, however, were sedated with pentobarbital to a burst suppression pattern. No electrolyte disorders were found in normothermic patients, and there were no reports on rebound hyperkalemia during rewarming (46) . Therefore, as Cairns et al. (9) already concluded regarding barbiturate treatment, serum electrolytes have to be monitored closely during hypothermia and barbiturate treatment, and clinicians may tolerate or treat asymptomatic hypokalemia very carefully, rather than risk severe rebound hyperkalemia. Other general supportive intensive care measures such as tight glucose control, complicated by hypothermia-induced insulin resistance, as well as treatment of hypomagnesemia and cardiac arrhythmias, and controlled slow rewarming because of imminent rebound brain edema and pyrexia after rewarming are of high importance (3, 45, 51) . Possible side effects of hypothermia have to be detected early and treated proactively and vigorously to avoid that hypothermia adversely effects outcome. Clinicians applying systemic hypothermia should be carefully aware of its physiological and pathophysiological consequences leading to beneficial as well as potentially deleterious effects.
Limitations of the Study
A major limitation of the present study, especially regarding the analysis of side effects, is the fact that, in most cases, hypothermia was combined with barbiturate coma and osmotherapy. Therefore, infections as a result of immunosuppression and electrolyte disorders in several cases may not have been induced by hypothermia alone, but also by thiopenthal infusion, mannitol, or hypertonic hydroxyethyl starch solution (19, 52) . Furthermore, a multicenter study with randomized concurrent controls is desirable to define the true impact of hypothermia treatment in patients with SAH and resistant intracranial hypertension and/or CVS.
CONCLUSION
Prolonged systemic hypothermia with a target body core temperature of 33 to 35ЊC may be considered as a last-resort option for a carefully selected group of younger SAH patients with resistant intracranial hypertension or CVS. Good functional out-NEUROSURGERY VOLUME 64 | NUMBER 1 | JANUARY 2009 | 91 HYPOTHERMIA AND ANEURYSMAL SUBARACHNOID HEMORRHAGE come in these patients with most severe complications can be achieved in more than one-third of the cases. However, in most patients treated with long-term hypothermia, severe side effects occur and, therefore, require elaborated protocols in general intensive care unit management and experienced medical and nursing staff; e.g., staff especially trained regarding possible complications associated with hypothermia treatment.
Disclosure
